GlassScriptPhysician profile
Daniel S Winchester
NPI 1740628023
$4,342.32
in general payments reported to CMS, 2019-2025
20 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $283 · 2021: $694 · 2022: $942 · 2023: $589 · 2024: $800 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,319.19 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $830.59 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $270.44 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $193.12 | 2019-2024 | Ilumya |
| Galderma Laboratories, L.P. | $150.60 | 2019-2025 | Aklief, Oracea |
| Ucb, INC. | $114.02 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $90.03 | 2022-2024 | Tremfya |
| Incyte Corporation | $82.67 | 2021-2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $41.07 | 2020-2022 | |
| Lilly USA, LLC | $38.84 | 2022-2024 | Taltz, Ebglyss |
| Dusa Pharmaceuticals, INC. | $37.85 | 2019 | |
| Arcutis Biotherapeutics, INC. | $31.03 | 2024 | Zoryve |
| Acera Surgical, INC. | $25.74 | 2021-2022 | |
| Biofrontera INC. | $22.11 | 2019 | |
| Dermavant Sciences, INC. | $19.00 | 2024 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $18.15 | 2024 | |
| Organon LLC | $15.61 | 2025 | Vtama |
| Pfizer INC. | $14.41 | 2019 | |
| Amgen INC. | $14.15 | 2020 | |
| Kyowa Kirin, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Winchester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.